好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Evaluating the Concordance Between International Classification of Diseases, Tenth Revision Code, and Stroke Severity as Measured by the National Institutes of Health Stroke Scale
Cerebrovascular Disease and Interventional Neurology
P1 - Poster Session 1 (8:00 AM-9:00 AM)
5-013

To use the National Institutes of Health Stroke Scale (NIHSS) as reported in Paul Coverdell Stroke Registry (PCSR) to assess the accuracy of the ICD-10-based NIHSS as a measure of Acute Ischemic Stroke (AIS) severity.

NIHSS score is used to evaluate stroke severity in clinical settings, typically close to admission, whereas the ICD-10 NIHSS is used for billing. The validity of stroke severity from billing registries remains uncertain. 

In this observational study, we analyzed data from a dataset linking the PCSR and Medicare databases, sampling 148,759 patients aged 65 and above admitted for AIS from 2016 to 2019.  We examined the concordance between clinical NIHSS scores documented in PCSR and ICD-10-based NIHSS from Medicare claims data, treating both as continuous variables. Discordance was measured by calculating the absolute difference between the PCSR and ICD-10-based NIHSS scores.  We explored demographic and clinical factors associated with score discordance across nine different states. 

64,684 patients had documentation of both clinical and ICD-10 NIHSS scores. The mean NIHSS score from PCSR was 7.25 (SD=7.80), and the mean from ICD-10 was 7.55 (SD = 7.82). There was a high concordance between the two scores with Concordance Correlation Coefficient of 0.92 (95% CI: 0.914 - 0.920, P < 0.001), and a linear regression beta coefficient of 0.91 (95% CI: 0.9159 - 0.9220, P < 0.001). The average discordance was 1.2 points (SD = 2.9). State-specific discordance ranged from a minimum of 0.69 (SD = 2.27) in Massachusetts to a maximum of 1.73 (SD = 3.65) in California.

The observed high concordance between clinical and ICD-10 NIHSS scores signals that ICD-10 NIHSS scores can be used as a valid proxy in assessing stroke severity, offering valuable clinical, academic, and administrative implications.

Authors/Disclosures
Lidia Maria V. Moura, MD, PhD, MPH, FAAN (Massachusetts General Hospital)
PRESENTER
Dr. Moura has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Moura has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. The institution of Dr. Moura has received research support from Centers for Diseases Control and Prevention (CDC SIP20-007) . The institution of Dr. Moura has received research support from Epilepsy Foundation of America . The institution of Dr. Moura has received research support from NIH - NIA and NINDS. Dr. Moura has received personal compensation in the range of $50,000-$99,999 for serving as a Expert Advisor with Epilepsy Foundation .
Mohamed Taha, MD (Cleveland Clinic Foundation) Dr. Taha has nothing to disclose.
Mamoon Habib Mamoon Habib has nothing to disclose.
Victor Lomachinsky No disclosure on file
Peter N. Hadar, MD (Massachusetts General Hospital) Dr. Hadar has or had stock in AIMSS.Dr. Hadar has or had stock in NeedleGPS.Dr. Hadar has received research support from NIH NINDS. Dr. Hadar has received research support from Susan Spencer Scholarship of the 好色先生/American Epilepsy Society/Epilepsy Foundation/American Brain Foundation.
Joseph Newhouse (Harvard University) Joseph Newhouse has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for National Committee for Quality Assurance. Joseph Newhouse has received publishing royalties from a publication relating to health care.
Lee H. Schwamm, MD, FAAN (Yale New Haven Health System) Dr. Schwamm has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Prime 好色先生. Dr. Schwamm has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Schwamm has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for lifeimage. Dr. Schwamm has received personal compensation in the range of $500-$4,999 for serving as a Consultant for mediasphere. Dr. Schwamm has received personal compensation in the range of $500-$4,999 for serving as a Consultant for medscape/WebMD. Dr. Schwamm has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for medtronic. Dr. Schwamm has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Penumbra. Dr. Schwamm has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. The institution of Dr. Schwamm has received research support from NINDS. The institution of Dr. Schwamm has received research support from PCORI. Dr. Schwamm has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Schwamm has received publishing royalties from a publication relating to health care. Dr. Schwamm has a non-compensated relationship as a Board of directors with American heart association that is relevant to AAN interests or activities.
Deborah Blacker Deborah Blacker has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Belvoir inc. The institution of Deborah Blacker has received research support from NIH.